CTI BioPharma

CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.

Earnings data Q1 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CTI BioPharma Corp. a biopharmaceutical company, develops, acquires, and commercializes oncology products for cancer treatment. Its development portfolio includes Pixantrone, a phase III trial product, for non-Hodgkin's lymphoma; Brostallicin, which is in a first-line Phase II study for the treatment of sarcoma; and OPAXIO, a chemotherapeutic agent for the potential treatment of non-small cell lung, ovarian, and other cancers. It has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd.; and PG-TXL Company, L.P.

Arbutus Biopharma

IronNet

Tellurian

Penny stocks to buy for under $5 that have unusual options activity right now. The post 4 Penny Stocks To Buy For Under $5 With Unusual Options Activity appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks To Buy For Under $5 With Unusual Options Activity

CTIC's Pacritinib approval was delayed by three months on what appears to be a major safety data amendment. Pacritinib has a lot of baggage.

CTI BioPharma: Long And Troubled History, Finally Approaching Approval

Alzamend Neuro

Katapult Holdings

Progenity

5 penny stocks analysts say are a buy right now with hefty price targets. The post Penny Stocks To Buy According To 5 Analysts With 55%-246% Targets appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy According To 5 Analysts With 55%-246% Targets

SEATTLE, Dec. 13, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) announced five scientific poster presentations on the pacritinib clinical program at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, being held as a hybrid (virtual and live) meeting in Atlanta, Georgia, December 11-14, 2021. "We are pleased with the growing body of clinical evidence supporting the potential of pacritinib's unique place in treating cytopenic myelofibrosis, specifically in patients with moderate or severe thrombocytopenia, a notable challenge in light of the significant limitations of approved therapies," said Adam R.

CTI BioPharma Presents Data from Pacritinib Program at the 63rd American Society of Hematology Meeting

Cocrystal Pharma

Eton Pharmaceuticals Inc

ObsEva

These biotech penny stocks could be worth watching after recent announcements The post 4 Biotech Penny Stocks to Watch With New Catalysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Biotech Penny Stocks to Watch With New Catalysts

Corvus Pharmaceuticals

BurgerFi

Navigator Hlds

The Real Good Food Co

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 White-Hot Stocks Trading Under $10 to Buy Now Have Great Upside Potential

The stock price of CTI BioPharma Corp (NASDAQ: CTIC) increased by over 15% during intraday trading today. This is why it happened.

CTI BioPharma (CTIC) Stock: Why The Price Surged Today

Cidara Therapeutics

Cumberland Pharma

Penny stocks to watch even with Biotech ETFs heading lower today. The post 3 Biotech Penny Stocks To Watch With The Stock Market Down Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Biotech Penny Stocks To Watch With The Stock Market Down Today

SEATTLE, Dec. 2, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the JMP Securities Hematology & Oncology Summit at 3:40 p.m. ET. The conference will be held in a virtual meeting format.

CTI BioPharma to Present at the JMP Securities Hematology & Oncology Summit on Monday, December 6

The FDA extended its review period for myelofibrosis candidate pacritinib.

Why CTI BioPharma Stock Is Plunging Today

The stock price of CTI BioPharma Corp. (Nasdaq: CTIC) fell by over 14% pre-market today. This is why it happened.

CTI BioPharma (CTIC) Stock: Why The Price Fell Today

The FDA has extended the review period for CTI BioPharma Corp's (NASDAQ: CTIC) pacritinib marketing application for myelofibrosis. The application for pacritinib covers adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a baseline platelet count of over 50 × 109/L.

FDA Extends Review Period For CTI BioPharma's Bone Marrow Cancer Candidate

SEATTLE, Nov. 30, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for pacritinib for the treatment of adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) with a baseline platelet count of

CTI BioPharma Announces Extension of FDA Review Period for Pacritinib in Myelofibrosis with Severe Thrombocytopenia

Investors need to pay close attention to CTI BioPharma (CTIC) stock based on the movements in the options market lately.

Implied Volatility Surging for CTI BioPharma (CTIC) Stock Options

SEATTLE, Nov. 4, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced five poster presentations from the Company's pacritinib program at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, being held virtually and in Atlanta, Georgia, December 11-14, 2021. The details of the poster presentations are as follows: Abstract Title: A Retrospective Head-to-Head Comparison between Pacritinib and Ruxolitinib in Patients with Myelofibrosis and Moderate to Severe Thrombocytopenia Publication Number: 3639  Session Name: 634.

CTI BioPharma Announces Presentations at the 63rd American Society of Hematology Meeting

CTI BioPharma (CTIC) posts top-line data from the PRE-VENT study evaluating pacritinib/standard of care as a treatment of severe COVID-19 infection.

CTI BioPharma (CTIC) Dips on Top-Line Data from COVID-19 Study

CTI BioPharma Corp (NASDAQ: CTIC) has announced topline results from the PRE-VENT trial of pacritinib in hospitalized COVID-19 patients. The final PRE-VENT analysis was conducted following the randomization of 200 patients.

CTI BioPharma's COVID-19 Candidate Misses Primary Endpoint Mark In Phase 2 Trial

SEATTLE, Oct. 1, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced topline results from the PRE-VENT trial (NCT04404361) of pacritinib in hospitalized patients with severe COVID-19. PRE-VENT, a randomized, double-blind, placebo-controlled multicenter study, compared pacritinib/standard of care versus placebo/standard of care in hospitalized patients with severe COVID-19, including patients with and without cancer.

CTI BioPharma Announces Topline Data from Final Analysis of the PRE-VENT Clinical Trial Evaluating Pacritinib as a Treatment for Severe COVID-19

Bellus Health Inc

Pieris Pharma

These penny stocks could be in focus as we turn the page on a new month. The post 5 Penny Stocks To Watch For September With Upcoming Events appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Watch For September With Upcoming Events

The stock price of CTI BioPharma Corp. (Nasdaq: CTIC) increased by over 5% pre-market. This is why it happened.

CTIC Stock: Over 5% Increase Pre-Market Explanation

SEATTLE and TORONTO, Aug. 25, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) (CTI) and DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (DRI) today announced transactions totaling up to $135 million in funding for CTI, with $50 million in secured debt to be funded at closing and $60 million to purchase a tiered royalty on sales of pacrinitib upon product approval of pacrinitib by the U.S. Food and Drug Administration (FDA). The proceeds of the transactions will be used by CTI to fund the commercialization of pacritinib for the treatment of myelofibrosis patients with severe thrombocytopenia.

CTI BioPharma and DRI Healthcare Trust Announce up to $135 Million Debt and Royalty Transaction

SEATTLE, Aug. 24, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks has overseen the launch of numerous hematology and cancer therapies at large pharmaceutical and biotech companies, including Kite Pharma, Amgen, and Genentech.

CTI BioPharma Announces Appointment of Diane Parks to Its Board of Directors

CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q2 2021 Results - Earnings Call Transcript

SEATTLE, Aug. 5, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the second quarter ended June 30, 2021. "This past quarter, we continued to advance pacritinib towards a potential U.S. approval and commercial launch this year.

CTI BioPharma Reports Second Quarter 2021 Financial Results

SEATTLE, July 29, 2021 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its second quarter 2021 financial results on Thursday, August 5, 2021, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a conference call and webcast to discuss the results and provide a general corporate update at 4:30 p.m.

News for CTI BioPharma Stock (CTIC)